204 related articles for article (PubMed ID: 37388717)
21. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
[TBL] [Abstract][Full Text] [Related]
22. Neurokinin B and Neurokinin-3 Receptor Signaling: Promising Developments in the Management of Menopausal Hot Flushes.
Modi M; Dhillo WS
Semin Reprod Med; 2019 May; 37(3):125-130. PubMed ID: 31869840
[TBL] [Abstract][Full Text] [Related]
23. Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review.
Menown SJ; Tello JA
Adv Ther; 2021 Oct; 38(10):5025-5045. PubMed ID: 34514552
[TBL] [Abstract][Full Text] [Related]
24. Neurokinin 3 Receptor Antagonism: A Novel Treatment for Menopausal Hot Flushes.
Modi M; Dhillo WS
Neuroendocrinology; 2019; 109(3):242-248. PubMed ID: 30504731
[TBL] [Abstract][Full Text] [Related]
25. Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic Review.
Abdi F; Mobedi H; Mosaffa N; Dolatian M; Ramezani Tehrani F
Arch Iran Med; 2016 Feb; 19(2):141-6. PubMed ID: 26838086
[TBL] [Abstract][Full Text] [Related]
26. Neurokinin 3 receptor antagonists - prime time?
Prague JK
Climacteric; 2021 Feb; 24(1):25-31. PubMed ID: 33135940
[TBL] [Abstract][Full Text] [Related]
27. Managing menopausal vasomotor symptoms in older women.
Stuenkel CA
Maturitas; 2021 Jan; 143():36-40. PubMed ID: 33308634
[TBL] [Abstract][Full Text] [Related]
28. Adipokines, adiposity, and vasomotor symptoms during the menopause transition: findings from the Study of Women's Health Across the Nation.
Thurston RC; Chang Y; Mancuso P; Matthews KA
Fertil Steril; 2013 Sep; 100(3):793-800. PubMed ID: 23755948
[TBL] [Abstract][Full Text] [Related]
29. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice.
Villaseca P
Climacteric; 2012 Apr; 15(2):115-24. PubMed ID: 22148909
[TBL] [Abstract][Full Text] [Related]
30. New advances in menopause symptom management.
Koysombat K; McGown P; Nyunt S; Abbara A; Dhillo WS
Best Pract Res Clin Endocrinol Metab; 2024 Jan; 38(1):101774. PubMed ID: 37076317
[TBL] [Abstract][Full Text] [Related]
31. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women.
Blümel JE; Chedraui P; Baron G; Belzares E; Bencosme A; Calle A; Danckers L; Espinoza MT; Flores D; Gomez G; Hernandez-Bueno JA; Izaguirre H; Leon-Leon P; Lima S; Mezones-Holguin E; Monterrosa A; Mostajo D; Navarro D; Ojeda E; Onatra W; Royer M; Soto E; Tserotas K; Vallejo S;
Menopause; 2011 Jul; 18(7):778-85. PubMed ID: 21407137
[TBL] [Abstract][Full Text] [Related]
32. The neurokinin B pathway in the treatment of menopausal hot flushes.
Anderson RA; Skorupskaite K; Sassarini J
Climacteric; 2019 Feb; 22(1):51-54. PubMed ID: 30572747
[TBL] [Abstract][Full Text] [Related]
33. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review.
Utian WH
Health Qual Life Outcomes; 2005 Aug; 3():47. PubMed ID: 16083502
[TBL] [Abstract][Full Text] [Related]
34. Hormone Therapy and Other Treatments for Symptoms of Menopause.
Hill DA; Crider M; Hill SR
Am Fam Physician; 2016 Dec; 94(11):884-889. PubMed ID: 27929271
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
[TBL] [Abstract][Full Text] [Related]
36. Managing vasomotor symptoms in women after cancer.
Pinkerton JV; Santen RJ
Climacteric; 2019 Dec; 22(6):544-552. PubMed ID: 31081391
[TBL] [Abstract][Full Text] [Related]
37. Vasomotor symptoms and management of women undergoing treatment for breast cancer: literature review with focus on the therapeutic potential of cytoplasmic pollen extract.
Lello S; Paris I; Cagnacci A; Sartori D; Caruso S; Iop A
Gynecol Endocrinol; 2023 Dec; 39(1):2162035. PubMed ID: 36591791
[TBL] [Abstract][Full Text] [Related]
38. The 2017 hormone therapy position statement of The North American Menopause Society.
Menopause; 2018 Nov; 25(11):1362-1387. PubMed ID: 30358733
[TBL] [Abstract][Full Text] [Related]
39. Vasomotor symptom characteristics: are they risk factors for incident diabetes?
Gray KE; Katon JG; LeBlanc ES; Woods NF; Bastian LA; Reiber GE; Weitlauf JC; Nelson KM; LaCroix AZ
Menopause; 2018 May; 25(5):520-530. PubMed ID: 29206771
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States.
Stute P; Cano A; Thurston RC; Small M; Lee L; Scott M; Siddiqui E; Schultz NM
Maturitas; 2022 Oct; 164():38-45. PubMed ID: 35785563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
